The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

FOY     [N'-[5-(4- ethoxycarbonylphenoxy) carbonylpe...

Synonyms: AG-J-78129, LS-35906, CTK8F9977, AC1L272G, Gabexato mesilato, ...
This record was replaced with 3447.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of gabexate


Psychiatry related information on gabexate

  • To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9 [6].

High impact information on gabexate


Chemical compound and disease context of gabexate


Biological context of gabexate

  • CONCLUSIONS: In a limited number of patients (n = 34), gabexate mesylate (2 mg/kg/hr) could not inhibit coagulation or fibrinolysis and gabexate mesylate could not improve the DIC score or mortality rate in pre- or mild DIC [15].
  • Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs [16].
  • We propose that platelet count, coagulation factor levels, and FDP may be useful for the early detection of VOD, and an anticoagulant drug such as FOY is worthy of consideration for the prevention and treatment of VOD [17].
  • Preoperative administration of gabexate mesilate (preop GM group) substantially ameliorated hepatic I/R injury as compared with the other patients (intraop and without GM groups); postoperative serum transaminase levels were notably decreased in association with marked suppression of IL-6 levels in blood circulation during liver surgery [18].
  • Differences in gabexate mesylate affinities for these proteases reflect structural differences at their primary specificity subsite, which have been investigated by comparative analysis of amino acid sequences and by computer-graphics techniques [19].

Anatomical context of gabexate


Associations of gabexate with other chemical compounds


Gene context of gabexate


Analytical, diagnostic and therapeutic context of gabexate


  1. Gabexate mesilate in human acute pancreatitis. Yoshida, T. Gastroenterology (1993) [Pubmed]
  2. Gabexate as a therapy for disseminated intravascular coagulation. Umeki, S., Adachi, M., Watanabe, M., Yaji, S., Soejima, R. Arch. Intern. Med. (1988) [Pubmed]
  3. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Yoon, W.H., Jung, Y.J., Kim, T.D., Li, G., Park, B.J., Kim, J.Y., Lee, Y.C., Kim, J.M., Park, J.I., Park, H.D., No, Z.S., Lim, K., Hwang, B.D., Kim, Y.S. Clin. Cancer Res. (2004) [Pubmed]
  4. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. Chen, C.L., Wang, S.D., Zeng, Z.Y., Lin, K.J., Kao, S.T., Tani, T., Yu, C.K., Wang, J.Y. J. Allergy Clin. Immunol. (2006) [Pubmed]
  5. Modification of BHA forestomach carcinogenesis in rats: inhibition by diethylmaleate or indomethacin and enhancement by a retinoid. Shibata, M.A., Hirose, M., Masuda, A., Kato, T., Mutai, M., Ito, N. Carcinogenesis (1993) [Pubmed]
  6. Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Rha, S.Y., Jeung, H.C., Roh, J.K., Kim, J.J., Noh, S.H., Min, J.S., Kim, B.S., Chung, H.C. Int. J. Mol. Med. (2002) [Pubmed]
  7. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Ohshio, G., Saluja, A.K., Leli, U., Sengupta, A., Steer, M.L. Gastroenterology (1989) [Pubmed]
  8. Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C. Ito, N., Kawata, S., Tamura, S., Kiso, S., Tsushima, H., Maeda, Y., Yamasaki, E., Igura, T., Matsuzawa, Y. Hepatology (1996) [Pubmed]
  9. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Heinrich, S., Schäfer, M., Rousson, V., Clavien, P.A. Ann. Surg. (2006) [Pubmed]
  10. Proteinase inhibitors block formation of pemphigus acantholysis in experimental models of neonatal mice and skin explants: effects of synthetic and plasma proteinase inhibitors on pemphigus acantholysis. Naito, K., Morioka, S., Nakajima, S., Ogawa, H. J. Invest. Dermatol. (1989) [Pubmed]
  11. Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats. Hirata, M., Hayashi, I., Yoshimura, K., Ishii, K., Soma, K., Ohwada, T., Kakita, A., Majima, M. Br. J. Pharmacol. (2002) [Pubmed]
  12. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Kumon, K., Tanaka, K., Nakajima, N., Naito, Y., Fujita, T. Crit. Care Med. (1984) [Pubmed]
  13. Survival from DIC following amniotic fluid embolism. Successful treatment with a serine proteinase inhibitor; FOY. Taenaka, N., Shimada, Y., Kawai, M., Yoshiya, I., Kosaki, G. Anaesthesia. (1981) [Pubmed]
  14. The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. Dabrowski, A., Gabryelewicz, A. J. Physiol. Pharmacol. (1994) [Pubmed]
  15. Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation? Nishiyama, T., Matsukawa, T., Hanaoka, K. Crit. Care Med. (2000) [Pubmed]
  16. Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Uchiba, M., Okajima, K., Kaun, C., Binder, B.R., Wojta, J. Crit. Care Med. (2003) [Pubmed]
  17. Veno-occlusive disease of the liver after combined adjuvant chemotherapy for a 1-year-old boy with rhabdomyosarcoma: potential usefulness of the gabexate mesylate (FOY). Adachi, N., Matsuda, I. J. Pediatr. Gastroenterol. Nutr. (1992) [Pubmed]
  18. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. Kim, Y.I., Hwang, Y.J., Song, K.E., Yun, Y.K., Lee, J.W., Chun, B.Y. J. Am. Coll. Surg. (2002) [Pubmed]
  19. Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. Menegatti, E., Bolognesi, M., Scalia, S., Bortolotti, F., Guarneri, M., Ascenzi, P. Journal of pharmaceutical sciences. (1986) [Pubmed]
  20. Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. Nishijima, J., Hiraoka, N., Murata, A., Oka, Y., Kitagawa, K., Tanaka, N., Toda, H., Mori, T. J. Leukoc. Biol. (1992) [Pubmed]
  21. The effects of inhaled nitric oxide, gabexate mesilate, and retrograde flush in the lung graft from non-heart beating minipig donors. Luh, S.P., Tsai, C.C., Shau, W.Y., Chen, J.S., Kuo, S.H., Lin-Shiau, S.Y., Lee, Y.C. Transplantation (2000) [Pubmed]
  22. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Kushimoto, S., Johno, M., Naruo, M., Okabe, H., Takatsuki, K. Crit. Care Med. (1997) [Pubmed]
  23. Gabexate mesilate prevents compression-induced spinal cord injury. Young, W. Crit. Care Med. (1997) [Pubmed]
  24. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Sendo, T., Itoh, Y., Goromaru, T., Sumimura, T., Saito, M., Aki, K., Yano, T., Oishi, R. Br. J. Pharmacol. (2003) [Pubmed]
  25. Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Erba, F., Fiorucci, L., Pascarella, S., Menegatti, E., Ascenzi, P., Ascoli, F. Biochem. Pharmacol. (2001) [Pubmed]
  26. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY). Taenaka, N., Shimada, Y., Hirata, T., Nishijima, M., Yoshiya, I. Crit. Care Med. (1982) [Pubmed]
  27. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Andriulli, A., Leandro, G., Clemente, R., Festa, V., Caruso, N., Annese, V., Lezzi, G., Lichino, E., Bruno, F., Perri, F. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  28. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. Yuksel, M., Okajima, K., Uchiba, M., Okabe, H. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  29. Differential cytokine response in host defence mechanisms triggered by gram-negative and gram-positive bacteria, and the roles of gabexate mesilate, a synthetic protease inhibitor. Iwadou, H., Morimoto, Y., Iwagaki, H., Sinoura, S., Chouda, Y., Kodama, M., Yoshioka, T., Saito, S., Yagi, T., Tanaka, N. J. Int. Med. Res. (2002) [Pubmed]
  30. Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. Colasanti, M., Persichini, T., Venturini, G., Menegatti, E., Lauro, G.M., Ascenzi, P. Biochem. Biophys. Res. Commun. (1998) [Pubmed]
  31. Effect of intraarterial active oxygen species on the rat pancreas. Tamura, K., Manabe, T., Andoh, K., Kyogoku, T., Oshio, G., Tobe, T. Hepatogastroenterology (1992) [Pubmed]
  32. Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep. Oedekoven, B., Bey, R., Mottaghy, K., Schmid-Schönbein, H. Thromb. Haemost. (1984) [Pubmed]
  33. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Harada, N., Okajima, K., Kushimoto, S. Crit. Care Med. (1999) [Pubmed]
  34. Hemodialysis using gabexate mesilate (FOY) in patients with a high bleeding risk. Taenaka, N., Terada, N., Takahashi, H., Tachimori, Y., Okada, T., Takezawa, J., Shimada, Y., Yoshiya, I. Crit. Care Med. (1986) [Pubmed]
WikiGenes - Universities